AU2021221725A1 - Improvements in and relating to compositions for alleviating the effects/symptoms of inflammation - Google Patents
Improvements in and relating to compositions for alleviating the effects/symptoms of inflammation Download PDFInfo
- Publication number
- AU2021221725A1 AU2021221725A1 AU2021221725A AU2021221725A AU2021221725A1 AU 2021221725 A1 AU2021221725 A1 AU 2021221725A1 AU 2021221725 A AU2021221725 A AU 2021221725A AU 2021221725 A AU2021221725 A AU 2021221725A AU 2021221725 A1 AU2021221725 A1 AU 2021221725A1
- Authority
- AU
- Australia
- Prior art keywords
- extract
- effects
- symptoms
- glucosamine sulphate
- glm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Our Ref: 317503 A nutraceutical composition consisting of glucosamine sulphate; and green-lipped mussel (Perna canaliculus) extract; for alleviating the symptoms and/or effects related to osteoarthritis. 13
Description
Our Ref: 317503
The present invention relates to nutraceutical compositions for alleviating the effects and/or symptoms of osteoarthritis (OA) and uses therefor. In particular, the present invention relates to nutraceutical compositions comprising green-lipped mussel (Perna canaliculus) extract and glucosamine sulphate.
There is a need in the art for economical and/or alternative methods for helping to alleviate the effects and/or symptoms of inflammation including OA.
There is also a need in the art to be able to economically formulate nutraceutical oral compositions which can be effectively employed to help alleviate the effects and/or symptoms of inflammation including OA, which can enter a mammalian host via mucosal membranes.
There is also a need in the art to have an economical approach to combine green-lipped mussel (Perna canaliculus) extract and glucosamine sulphate that are beneficial in alleviating the effects and/or symptoms of inflammation including OA.
There is also a need for effective cost and relatively inexpensive alternatives to current compositions or drugs for alleviating the effects and/or symptoms of inflammation including OA.
It is an object of the present invention to address the foregoing problems or at least to provide the public with a useful choice.
Glucosamine sulphate
Glucosamines are a group of amino monosaccharides naturally found in connective and cartilage tissues, to maintain their normal functions. Glucosamines are also known to alleviate the effects and/or symptoms of inflammation including OA, by their anti inflammatory properties.
Specifically, glucosamines stimulate the biochemical synthesis of mucopolysaccharides and increase the calcium intake in bones.
In addition, glucosamines can also improve the metabolic function and nutritional intakes of
Our Ref: 317503
bones and cartilage tissues, enhance the synthesis and increase the viscosity of synovial fluid to lubricate joints.
Consequently, glucosamines can block the pathological process of OA to prevent joint degeneration by alleviating inflammation.
Glucosamines can either be synthesized in a laboratory or be extracted from shells of shellfish such as shrimps and crabs.
There are several forms of glucosamines: glucosamine sulphate, glucosamine hydrochloride and N-acetyl glucosamine. Recent meta-data analysis shows that commonly used glucosamine hydrochloride does not provide convincing clinical results (Runhaar et al., 2017).
On the contrary, glucosamine sulphate at 1500mg daily dosage can positively affect cartilage structures and reduce pain in knee OA patients (Veronese et al., 2020). It has been further suggested that glucosamine sulphate in combination with other products, such as chondroitin or curcumin, may provide more further beneficial effects to OA patients (Ogata et al., 2018; Gugliandolo et al., 2020).
Green-lipped mussel
Green-lipped mussel (GLM), also known as Pema canaliculus, is endemic to New Zealand. When taken orally in whole powder or oil/lipid extract formats, GLM has been found to reduce pain and ameliorate other debilitating symptoms, associated with inflammatory diseases such as OA, without causing the adverse side effects of non-steroidal anti inflammatories (NSAIDs).
The underlying mechanisms explaining the effects of GLM, are in the anti-inflammatory activity of bioactive lipids in GLM, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
These lipids mediate the anti-inflammatory response by inhibiting both the cyclo-oxygenase (COX) and lipo-oxygenase (LOX) cascades of arachidonic acid (AA) metabolism, thereby resulting in a decrease in the synthesis of pro-inflammatory prostaglandins and leukotrienes.
Furthermore, GLM is reported to contain novel bioactive lipids such as pro-resolving lipid mediators which reduce inflammation through counter-regulating pro-inflammatory cytokines, clearing apoptotic neutrophils, and inducing wound healing and tissue regeneration: thereby also ameliorating the effects and/or symptoms of inflammation including OA.
Several clinical studies concluded that GLM, at a dose of around 1000mg per day, provided
Our Ref: 317503
moderate and clinically meaningful treatment effects on OA pain (Abshirini et al. 2021).
It is apparent in the art that glucosamines and GLM have different mechanisms of action and each works on a different pathway to alleviate OA effects and/or symptoms.
It would therefore be useful if there could be provided a nutraceutical composition comprising glucosamine sulphate and GLM for alleviating OA effects and/or symptoms.
The present invention is related to such a nutraceutical combination, comprising glucosamine sulphate with GLM extract.
AU2000071333 discloses a composition comprising glucosamine sulphate, GLM extract and methylsulfonylmethane which treats a subject for inflammatory diseases, such as an autoimmune disease, osteoarthritis, and rheumatoid arthritis. The composition in AU2000071333 by way of contrast to the present invention has more GLM extract therein than glucosamine sulphate, which is noteworthy as the cost of GLM extract is significantly greater than that of glucosamine sulphate.
Therefore, there is thus a need for new more cost effective compositions of glucosamine sulphate and GLM extract which can also alleviate inflammatory conditions, and/or the symptoms/effects of OA.
It would also be useful if there could be provided compositions providing an improved effect in alleviating the effects and/or symptoms of inflammation including OA including reducing inflammation and/or reducing the production of TNF-a.
Nutraceutical compositions of the present invention provide surprising anti-inflammatory effects and possible symptom reduction as shown in the in vitro experiments.
All references, including any patents or patent applications cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art.
The discussion of the references states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents.
It will be clearly understood that, although one or more prior art publications may be referred to herein, any such references do not constitute an admission that any of these documents form part of the common general knowledge in the art, in Australia, New Zealand or in any other country.
Throughout this specification, the word "comprise", or variations thereof such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step,
Our Ref: 317503
or group of elements integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
Further aspects and advantages of the present invention will become apparent from the ensuing description which is given by way of example only.
The term 'glucosamine' as used herein refers to an amino sugar with the molecular formula of C 6 H 1 3N0 5and is a commonly used dietary supplement.
The term 'glucosamine sulphate' as used herein refers to a form of glucosamine with the molecular formula of C6 H 1 NOS and is a stable form of glucosamine.
The term 'green-lipped mussel' as used herein refers to Pema canaliculus, which is also known as the New Zealand mussel, the greenshell mussel, kuku, and kutai, and is a bivalve mollusc in the Mytilidae family.
The term 'osteoarthritis' or 'OA"as used herein refers to a type of degenerative joint disease resulting from breakdown of joint cartilage and underlying bone, with the most common symptoms being joint pain and stiffness.
The term 'lipid' as used herein refers to a micro biomolecule that is soluble in nonpolar solvents, which are typically hydrocarbons used to dissolve other naturally occurring hydrocarbon lipid molecules that do not, or do not easily dissolve in water. For example, fatty acids are common components of complex lipids.
The term 'extract' as used herein refers to the resulting oil/lipid product of an extraction process, and may be in the form of a powder.
The term 'effective amount' as used herein refers to an amount of an active component of the present invention which when the oral composition is taken in a dosage quantity will be effective in helping to alleviate the symptoms of inflammation including OA in a mammal.
The term 'effective amount'when used herein may also in some embodiments refer to a therapeutically effective amount of an active component of the present invention which when the oral composition is taken in a dosage quantity can alleviate or mitigate the symptoms of inflammation including OA.
In some embodiments, the effective amount will be the same as the dosage quantity. In other embodiments, the effective amount may be half, quarter, or a third, of the dosage quantity. In other embodiments, the effective amount may be greater than the dosage quantity in the range of two to ten times of the dosage quantity.
Our Ref: 317503
The term 'dosage form', also known as 'unit dose', as used herein refers to nutraceutical products in the form in which they are marketed for use, with a specific mixture of active ingredients and inactive components (excipients), in a particular configuration (such as a capsule shell, for example), and apportioned into a particular dose.
The term 'dosage quantity' as used herein refers to the relative amount of the active components of the oral composition of the present invention which when taken at a particular time or series of times can induce a positive biological or medical response in a human or other mammal. In preferred embodiments the term 'dosage quantity' as used herein refers to the following observed effects:
- can help alleviate or mitigate, the symptoms and/or effects of OA; and/or
- can alleviate or mitigate, the symptoms and/or effects of OA.
It should be appreciated that the dosage quantity may be adjusted as required depending on the subject to be treated.
For example only, a dosage quantity may be a single tablet of the present invention; or dosage quantity may be a part thereof - e.g. half a tablet; or a dosage quantity may be multiple tablets e.g. 2 tablets. As mentioned, a dosage quantity is envisaged to be taken more than once a day to maintain the availability of the active components within a person or animal.
It should be appreciated that the relative amount of the active components may be adjusted as required depending on the subject to be treated. The examples given herein should be seen as exemplary and base lines for re-adjusting the oral composition and/or dosage amount as required as would be taken into account by a person skilled in the art.
The terms 'treatment', 'treat' and 'treating' as used herein refer to a subject taking the nutraceutical composition of the present invention after the onset of a clinical manifestation of a disease state or condition, such as OA, so as to eliminate or reduce the symptoms and/or effects of said OA, or clinical manifestation of the disease state or condition.
The present invention has particular application to alleviating the effects and/or symptoms of inflammation including OA. In particular, the present invention is concerned with reducing inflammation. More specifically, the present invention is concerned with reducing the production of Tumour Necrosis Factor alpha (TNF-a), an inflammatory cytokine produced during inflammation. While it is known that glucosamine sulphate and GLM extract can each positively affect the cartilage structures and reduce pain in OA patients, studies have shown
Our Ref: 317503
that their individual effects on OA are via different modes of action.
The inventor was therefore interested to explore whether or not a combination of just these two ingredients could have additional positive effects on people suffering from inflammatory conditions including OA.
According to a first aspect of the present invention, there is provided a nutraceutical composition consisting of:
• glucosamine sulphate; and • green-lipped mussel (Perna canaliculus) extract;
for alleviating the symptoms and/or effects related to osteoarthritis.
According to a second aspect of the present invention, there is provided a nutraceutical composition consisting of:
• glucosamine sulphate; and • green-lipped mussel (Perna canaliculus) extract;
for reducing inflammation.
According to a third aspect of the present invention, there is provided a nutraceutical composition comprising:
• glucosamine sulphate; and • green-lipped mussel (Perna canaliculus) extract;
as the main active ingredients
wherein glucosamine sulphate and green-lipped mussel (Perna canaliculus) extract are respectively present in a 5:3 ratio; for alleviating the symptoms and/or effects related to osteoarthritis.
According to a fourth aspect of the present invention, there is provided a nutraceutical composition comprising the following:
• glucosamine sulphate; and • green-lipped mussel (Perna canaliculus) extract;
wherein glucosamine sulphate and green-lipped mussel (Perna canaliculus) extract are respectively present in a 5:3 ratio; for alleviating the symptoms and/or effects of osteoarthritis.
According to a fifth aspect of the present invention, there is provided a nutraceutical
Our Ref: 317503
composition comprising:
• at least substantially 500mg of glucosamine sulphate; and • at least substantially 300mg green-lipped mussel (Pema canaliculus) extract;
for alleviating the symptoms and/or effects related to osteoarthritis.
Preferably, the nutraceutical composition is for oral administration.
Preferably, the nutraceutical composition is in the form of a capsule.
Preferably, the nutraceutical composition is in a suitable dosage form as determined by a person skilled in the art.
Preferably, the nutraceutical composition is to be taken in a dosage quantity comprising substantially 900mg GLM extract and 1500mg glucosamine sulphate daily for most people regardless of age and sex. However, for persons with extreme weight, such as those weighing below 40kg or above 100kg, the nutraceutical composition may be given in the dosage quantity determined by dietitians or physicians.
According to a sixth aspect there is provided a nutraceutical composition substantially as described as above wherein the composition reduces inflammation and/or reduces the production of TNF-a.
According to a seventh aspect there is provided a method of treating OA comprising administering a dosage quantity of:
• glucosamine sulphate; and • green-lipped mussel (Perna canaliculus) extract;
to alleviate the effects and/or symptoms of an inflammatory condition; and/or
reduce inflammation and/or reduce the production of TNF-a.
Preferably, the nutraceutical composition is for oral administration, and in the form of a capsule comprising at least substantially 500mg glucosamine sulphate and at least substantially 300mg GLM extract to facilitate human intake.
The present invention comprising glucosamine sulphate and GLM at proper dosages allows each of the active ingredients to work on their respective pathways, thereby exerting beneficial effects in alleviating OA effects and/or symptoms.
Figure 1 The combination of glucosamine sulphate and GLM extract inhibits the
Our Ref: 317503
production of TNF-a in the mouse macrophage cell line RAW 264.7; and
Figure 2 The combination of glucosamine sulphate and GLM extract inhibits the production of TNF-a in the human monocyte cell line TPH-1.
EXAMPLE 1 - Inhibition of TNF-g production in mouse cell line
The anti-inflammatory effects of the combination comprising glucosamine sulphate and GLM extract were tested in cultured mouse macrophage cell line RAW264.7 cultured in Dulbecco's Modified Eagle Medium (DMEM) media. 0.01 pg/ml lipopolysaccharide (LPS), also known as endotoxin, was used to induce inflammatory-like responses in cultured RAW264.7 cells.
Upon stimulation, RAW264.7 cells overproduced around 5,000 ng/ml tumour necrosis factor a (TNF-a), indicating inflammation. The combination comprising glucosamine sulphate and GLM extract was added at concentrations of 5, 12.5 or 25 pg/ml to the LPS-stimulated RAW264.7 cells by dissolving the combination in the cell culture media.
Glucosamine sulphate was purchased from Sigma-Aldrich and GLM extract was prepared from OceanfitTMGLM powder in Professor Jun Lu's Biomedical Laboratory at Auckland University of Technology. Concentrations of the combination at 5, 12.5 or 25 pg/ml substantially correspond to the estimated range of body fluid concentrations of persons weighing between 50kg to 100kg who have taken the combination comprising 1500mg glucosamine sulphate and 900mg GLM extract.
After 24 hours incubation, TNF-a concentration in the cell culture media was measured using a commercially available TNF-a enzyme-linked immunosorbent assay (ELISA) kit according to manufacturer's instruction. All concentrations of the combination comprising glucosamine sulphate and GLM extract displayed approximately 20% inhibition of TNF-a production as shown in Figure 1, suggesting that the combination comprising glucosamine sulphate and GLM extract is able to alleviate inflammatory conditions by reducing the production of TNF-a.
In addition, 1 pg/ml dexamethasone, a glucocorticoid, was used as a positive control to show inhibition of TNF-a production in LPS-stimulated RAW264.7 cells. The experiments were conducted in triplicate.
EXAMPLE 2 - Inhibition of TNF-g production in human cell line
The anti-inflammatory effects of the combination comprising glucosamine sulphate and GLM extract were tested in cultured human monocyte cell line TPH-1 cultured in Roswell Park
Our Ref: 317503
Memorial Institute (RPMI) media. Similarly, 0.01 pg/ml LPS was used to induce inflammatory-like responses in cultured TPH-1 cells.
Upon stimulation, TPH-1 cells overproduced 375 ng/ml TNF-a, indicating inflammation. The combination comprising glucosamine sulphate and GLM extract was added at concentrations of 5, 12.5 or 25 pg/ml to the LPS-stimulated TPH-1 cells by dissolving the combination in the cell culture media.
Similarly, glucosamine sulphate was purchased from Sigma-Aldrich and GLM extract was prepared from OceanfitTMGLM powder in Professor Jun Lu's Biomedical Laboratory at Auckland University of Technology. Concentrations of the combination at 5, 12.5 or 25 pg/ml substantially correspond to the estimated range of body fluid concentrations of persons weighing between 50kg to 100kg who have taken the combination comprising 1500mg glucosamine sulphate and 900mg GLM extract.
After 6 hours incubation, TNF-a concentration in the cell culture media was measured using a commercially available TNF-a ELISA kit according to manufacturer's instruction. Specifically, at 12.5 pg/ml, the combination comprising glucosamine sulphate and GLM extract was able to reduce TNF-a production by approximately 50% as shown in Figure 2, suggesting that the combination comprising glucosamine sulphate and GLM extract is able to alleviate inflammatory conditions by reducing the production of TNF-a.
Again, 1 pg/ml dexamethasone, a glucocorticoid, was used as a positive control to show inhibition of TNF-a production in LPS-stimulated TPH-1 cells. These experiments were conducted in triplicate.
The invention may also be said broadly to consist in the parts, elements and features referred to or indicated in the specification of the application, individually or collectively, in any or all combinations of two or more of said parts, elements or features.
Aspects of the present invention have been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope thereof as defined in the appended claims.
Our Ref: 317503
Abshirini et al. Green-lipped (greenshell T M ) mussel (Perna canaliculus) extract supplementation in treatment of osteoarthritis: a systematic review. Inflammopharmacology (2021)
Gugliandolo et al. Dietary Supplementation with Palmitoyl-Glucosamine Co-Micronized with Curcumin Relieves Osteoarthritis Pain and Benefits Joint Mobility. Animals (Basel). (2020)
Ogata et al. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis. Clin Rheumatol. (2018)
Runhaar et al. Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank. Ann Rheum Dis. (2017)
Veronese et al. Glucosamine sulphate: an umbrella review of health outcomes. TherAdv Musculoskelet Dis. (2020)
Our Ref: 317503
1. A nutraceutical composition consisting of: " glucosamine sulphate; and " green-lipped mussel (Perna canaliculus) extract; for alleviating the symptoms and/or effects related to osteoarthritis.
2. A nutraceutical composition consisting of:
" glucosamine sulphate; and " green-lipped mussel (Perna canaliculus) extract; for reducing inflammation.
3. A nutraceutical composition consisting of: • glucosamine sulphate; and * green-lipped mussel (Perna canaliculus) extract; wherein glucosamine sulphate and green-lipped mussel (Perna canaliculus) extract are respectively present in a 5:3 mass ratio;
for alleviating the symptoms and/or effects related to osteoarthritis.
4. A nutraceutical composition comprising the following: • glucosamine sulphate; and * green-lipped mussel (Perna canaliculus) extract; wherein glucosamine sulphate and green-lipped mussel (Perna canaliculus) extract are respectively present in a 5:3 mass ratio; for alleviating the symptoms and/or effects of osteoarthritis. 5. A nutraceutical composition comprising: " at least substantially 500mg of glucosamine sulphate; and " at least substantially 300mg green-lipped mussel (Perna canaliculus) extract; for alleviating the symptoms and/or effects related to osteoarthritis.
6. A nutraceutical composition as claimed in any one of the preceding claims, wherein the composition is for oral consumption.
7. A nutraceutical composition as claimed in any one of the preceding claims, wherein the composition is in a suitable dosage form.
8. A nutraceutical composition as claimed in any one of the preceding claims, wherein the composition is to be taken daily in a dosage quantity comprising substantially 1500mg glucosamine sulphate and 900mg green-lipped mussel (Perna canaliculus) extract.
Our Ref: 317503
9. A nutraceutical composition as claimed in any one of the preceding claims, wherein the composition reduces inflammation and/or reduces the production of TNF-a.
10. A method of treating osteoarthritis comprising administering a dosage quantity of:
• glucosamine sulphate; and
* green-lipped mussel (Perna canaliculus) extract;
to alleviate the effects and/or symptoms of an inflammatory condition; and/or reduce inflammation and/or reduce the production of TNF-a.
Figure 1 25 Aug 2021
TNF-α Production (ng/ml) in mouse RAW 264.7 macrophasge cell line 6000
5000 2021221725
4000
3000
2000
1000
0 Untreated LPS Dexamethasone Glucosamine+mussel extract
0 LPS 0.01 ug/ml Dexamethasone 1 ug/ml 5 ug/ml 12.5 ug/ml 25 ug/ml
1/2
Figure 2
TNF-α Production (ng/ml) in cultured human TPH-1 monocyte cell line 400 2021221725
350
300
250
200
150
100
50
0 Untreated LPS Dexamethasone Glucosamine+mussel extract
0 LPS 0.01 ug/ml Dexamethasone 1 ug/ml 5 ug/ml 12.5 ug/ml 25 ug/ml
2/2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021221725A AU2021221725A1 (en) | 2021-08-25 | 2021-08-25 | Improvements in and relating to compositions for alleviating the effects/symptoms of inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021221725A AU2021221725A1 (en) | 2021-08-25 | 2021-08-25 | Improvements in and relating to compositions for alleviating the effects/symptoms of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021221725A1 true AU2021221725A1 (en) | 2023-03-16 |
Family
ID=85480441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021221725A Abandoned AU2021221725A1 (en) | 2021-08-25 | 2021-08-25 | Improvements in and relating to compositions for alleviating the effects/symptoms of inflammation |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021221725A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2347349A (en) * | 1997-05-21 | 2000-09-06 | Macfarlane Lab New Zealand Lim | A synergistic composition comprising mussel protein extract and glycosaminoglycan suitable for treatment of arthritis |
| WO2001001976A2 (en) * | 1999-07-06 | 2001-01-11 | Foodscience Corporation | Composition comprising an extract of perna canaliculus, methylsulfonylmethane and glucosamine |
| WO2008103813A1 (en) * | 2007-02-22 | 2008-08-28 | T.F.H. Publications, Inc. | Pet treat containing organic nutrients |
| DE102010003550A1 (en) * | 2010-03-31 | 2011-10-06 | Medivatis Gmbh | Feedstuff, useful for preventing and alleviating joint complaints and for preparing sausages, pellets or sticks, comprises glucosamine sulfate, green-lipped mussel powder or extract, and air-dried and/or cold-smoked, raw muscle meat |
| US20180055874A1 (en) * | 2014-08-05 | 2018-03-01 | James Sullivan | Fast acting joint relief formulations |
-
2021
- 2021-08-25 AU AU2021221725A patent/AU2021221725A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2347349A (en) * | 1997-05-21 | 2000-09-06 | Macfarlane Lab New Zealand Lim | A synergistic composition comprising mussel protein extract and glycosaminoglycan suitable for treatment of arthritis |
| WO2001001976A2 (en) * | 1999-07-06 | 2001-01-11 | Foodscience Corporation | Composition comprising an extract of perna canaliculus, methylsulfonylmethane and glucosamine |
| WO2008103813A1 (en) * | 2007-02-22 | 2008-08-28 | T.F.H. Publications, Inc. | Pet treat containing organic nutrients |
| DE102010003550A1 (en) * | 2010-03-31 | 2011-10-06 | Medivatis Gmbh | Feedstuff, useful for preventing and alleviating joint complaints and for preparing sausages, pellets or sticks, comprises glucosamine sulfate, green-lipped mussel powder or extract, and air-dried and/or cold-smoked, raw muscle meat |
| US20180055874A1 (en) * | 2014-08-05 | 2018-03-01 | James Sullivan | Fast acting joint relief formulations |
Non-Patent Citations (4)
| Title |
|---|
| "Flexibility Dietary Supplement", Brand: Healthaid Altrotone, Published on MINTEL GNPD, <URL: https://www.gnpd.com/sinatra/recordpage/752881/>, Published August 2007 according to MINTEL GNPD, Last Retrieved 9 November 2022 * |
| "Flexible Joints Tablets", Brand: HealthAid Osteoflex Plus, Published on MINTEL GNPD, <URL: https://www.gnpd.com/sinatra/recordpage/4426273/>, Published November 2016 according to MINTEL GNPD, Last Retrieved 9 November 2022 * |
| ARTG Entry 308882, "NZ Green Lipped Mussel + Glucosamin", Published on TGA ARTG, <URL: https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=308882&agid=%28PrintDetailsPublic%29&actionid=1> * |
| Cobb et al, "Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus", Clinical Rheumatology (2006), Vol 25, Pages 275–284 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Curtis et al. | Biological basis for the benefit of nutraceutical supplementation in arthritis | |
| Meng et al. | Daphnes Cortex and its licorice-processed products suppress inflammation via the TLR4/NF-κB/NLRP3 signaling pathway and regulation of the metabolic profile in the treatment of rheumatoid arthritis | |
| Cobb et al. | Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus | |
| WO2005112960A1 (en) | Treatment for asthma and arthritis and othe inflammatory diseases | |
| AU2014224710B2 (en) | Mixture of fatty acids for use in the treatment of inflammatory pathologies | |
| WO2014019268A1 (en) | Pharmaceutical composition for promoting nerve injury restoration and application thereof | |
| EP1617830A2 (en) | Esterified fatty acid composition | |
| Chen et al. | Regulating lipid metabolism in osteoarthritis: a complex area with important future therapeutic potential | |
| CN103566198A (en) | Application of gastrodia elata and gastrodin in the preparation of products for treating non-alcoholic fatty liver | |
| SafaaHussain et al. | Anti-inflammatory, anti-oxidant, and vasodilating effect of evening primrose oil in type 2 diabetic patients | |
| AU2021221725A1 (en) | Improvements in and relating to compositions for alleviating the effects/symptoms of inflammation | |
| CN105982911A (en) | Preparation method of high-viscoelasticity injection composed of glucosamine and sodium hyaluronate | |
| Zaidi | The Concept and Management of Wajaul Mafasil in Unani Medicine | |
| AU2023202817A1 (en) | Improvements in and relating to compositions, methods and uses, for: alleviating conditions caused by, or related to, chronic inflammation; and/or reducing chronic inflammation | |
| Buddhakala et al. | Anti-diabetic, anti-inflammatory and muscle relaxant activities of extracts from Spirogyra varians (Hassall) Kuetzing. | |
| CN113368220A (en) | AHCO composition, and preparation and application thereof | |
| Zhang et al. | Clinical efficacy and inflammatory factors in knee osteoarthritis with glucosamine hydrochloride plus meloxicam | |
| WO2010017403A2 (en) | Therapeutic compositions, devices and methods for observing treated tissues | |
| WO2014203200A1 (en) | Arginine and/or citrulline for use in the treatment and/or prevention of osteoarthritis | |
| NL2039507B1 (en) | Composition containing fish bone powder and plant extract for effective improvement in bone joint health | |
| CN118806879A (en) | Composition with bone and joint health care function and application thereof | |
| Sampoorna et al. | ORTHOLORD TABLETS: A Blend of Natural Ingredients Provides Nutritional Support for Joint Health | |
| Butawan et al. | Methylsulfonylmethane: Antiinflammatory actions and usage for arthritic conditions | |
| Repetyuk et al. | Effectiveness of a novel hydrolysate collagen formulation in the complex treatment and rehabilitation of patients with symptomatic knee osteoarthritis | |
| Kumar | Marine Botanicals as Nutraceuticals for Arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |